Medtronic Completes Acquisition of CathWorks to Strengthen Cardiovascular Diagnostics Portfolio

The acquisition follows a 2022 strategic partnership between the two companies that supported the commercial rollout of the CathWorks FFRangio® System in the United States, Europe, and Japan.

Medtronic plc has completed the acquisition of CathWorks, a privately held medical device company, in a deal valued at $585 million, strengthening its position in cardiovascular diagnostics and interventional cardiology.

The acquisition follows a 2022 strategic partnership between the two companies that supported the commercial rollout of the CathWorks FFRangio® System in the United States, Europe, and Japan. The transaction also includes potential undisclosed earn-out payments.

CathWorks’ FFRangio system uses artificial intelligence and advanced computational modeling to provide a physiological assessment of coronary artery disease directly from standard coronary angiograms. The system eliminates the need for invasive pressure wires and drug-induced hyperemia used in traditional fractional flow reserve (FFR) procedures.

According to Medtronic, the technology enables a full assessment of the coronary tree using a wire-free and drug-free approach, offering a less invasive alternative for evaluating blood flow restrictions in coronary arteries.

The acquisition comes after results from the ALL-RISE randomized controlled trial, presented at the 2026 American College of Cardiology conference. The study included more than 1,900 patients across 59 global sites and found that the CathWorks system was non-inferior to wire-based FFR in measuring major adverse cardiac events at one year. The trial also reported improved resource utilization and reduced procedure time.

Medtronic stated that integrating CathWorks into its cardiovascular portfolio will expand access to digital diagnostic tools and support physicians with data-driven decision-making in the treatment of coronary artery disease.

Executives from Medtronic noted that the acquisition aligns with its broader strategy of strengthening core medical device businesses through targeted investments in high-growth technologies. The company also highlighted its focus on expanding digital transformation within cardiovascular care.

CathWorks’ leadership described the acquisition as a continuation of its collaboration with Medtronic aimed at advancing diagnostic capabilities in catheterization labs.

Financially, Medtronic expects the acquisition to have an immaterial impact on fiscal year 2027 GAAP and adjusted earnings per share, with neutral to accretive effects thereafter.

Stay tuned for more such updates on Digital Health News